[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-disease-chronic-obstructive-copd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-disease-chronic-obstructive-copd":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,70,101,144,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100645433","reset-copd-cohort-real-time-monitoring-and-early-warning-in-copd-patients-receiving-home-nppv-100645433",false,"NCT07701096","RESET-COPD Cohort: Real-Time Monitoring and Early Warning in COPD Patients Receiving Home NPPV","A Multicenter Prospective Cohort Study for Real-Time Monitoring and Intelligent Early Warning Model Development in COPD Patients Receiving Home Noninvasive Positive Pressure Ventilation","RESET-COPD","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosis of COPD according to GOLD 2026 criteria, with post-bronchodilator FEV1\u002FFVC \\\u003C 0.70.\n* Severe airflow limitation, defined as FEV1 \\\u003C 50% of predicted value, corresponding to GOLD grade III-IV.\n* Chronic hypercapnic respiratory failure, defined as arterial PaCO₂ ≥ 53 mmHg or ≥ 7.0 kPa while breathing room air in a clinically stable state, that is, no acute exacerbation of COPD within at least 4 weeks before enrollment.\n\nExclusion Criteria:\n\n* Chronic respiratory failure caused by diseases other than COPD, including neuromuscular diseases, chest wall deformity, obstructive sleep apnea, or severe obesity with BMI \\> 35 kg\u002Fm².\n* Severe cardiovascular disease, including NYHA class IV heart failure or unstable angina.\n* Severe renal disease receiving long-term renal replacement therapy.\n* Expected survival of less than 1 year, including active malignancy or end-stage systemic disease.\n* Inability to complete the study, including cognitive impairment, psychiatric disease, inability to cooperate with NPPV, inability to use wearable devices, or inability to complete follow-up.\n* Refusal to participate in the study or refusal to sign informed consent.","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","OBSERVATIONAL","This is a multicenter prospective cohort study designed to develop and validate a multisensor-based real-time monitoring and intelligent early warning model for acute exacerbations in patients with chronic obstructive pulmonary disease receiving home noninvasive positive pressure ventilation.\n\nEligible participants will be adults with severe COPD and chronic hypercapnic respiratory failure who are receiving or newly initiating home noninvasive positive pressure ventilation. Participants will undergo baseline assessment and follow-up visits at 3, 6, and 12 months. Clinical data, arterial blood gas measurements, pulmonary function, exercise capacity, symptom burden, health-related quality of life, psychological status, home noninvasive ventilation parameters, adherence, device-related adverse events, healthcare utilization, acute exacerbations, hospitalizations, intensive care unit admissions, invasive mechanical ventilation, and mortality will be collected.\n\nContinuous physiological monitoring data, will be used to construct individualized stable baseline values and to identify digital warning signals. Digital warning events will be further adjudicated through symptom confirmation, treatment and healthcare utilization verification, exclusion of alternative explanations, and investigator assessment.\n\nThe study aims to establish a longitudinal clinical and physiological dataset for COPD patients receiving home noninvasive ventilation and to evaluate the performance of a multisensor-based early warning model for clinically confirmed acute exacerbations of COPD.",[25,26,27],"Pulmonary Disease, Chronic Obstructive (COPD)","Chronic Respiratory Failure With Hypercapnia","Noninvasive Ventilation","NOT_YET_RECRUITING","2026-07-08",{"date":31,"type":32},"2026-07-14","ACTUAL",{"date":34,"type":21},"2026-08-01",{"date":36,"type":21},"2028-07-31",{"name":38,"class":39},"Beijing Chao Yang Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100645172","effectiveness-and-efficiency-of-home-telemonitoring-and-non-invasive-ventilation-in-patients-with-copd-and-hypercapnia-evaleco-100645172","NCT07679646","Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)","Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia","EVALECO","Inclusion Criteria:\n\n1. Age between 50 and 90 years.\n2. Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to current Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, demonstrating non-fully reversible airflow limitation with a Forced Expiratory Volume in 1 second (FEV1) \\\u003C 50% of the predicted value confirmed by spirometry.\n3. Persistent hypercapnia, defined as PaCO2 \\> 53 mmHg documented for at least two weeks following an acute COPD exacerbation.\n4. History of two or more acute COPD exacerbations within the preceding year.\n5. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Prior ongoing treatment with home non-invasive ventilation (NIV) or Continuous Positive Airway Pressure (CPAP).\n2. Severe obstructive sleep apnea (OSA), defined as an Apnea-Hypopnea Index (AHI) \\>= 30.\n3. Inability of the patient or the primary caregiver to comprehend or operate the telemonitoring and NIV procedures.\n4. Estimated life expectancy of less than one year.\n5. Terminal heart failure (New York Heart Association \\[NYHA\\] Class III-IV) or unstable angina.\n6. Advanced renal insufficiency (creatinine clearance \\\u003C 30%) or inclusion in an active dialysis program.\n7. Hepatic cirrhosis or active inclusion in a liver transplant program.\n8. Severe psychiatric illness requiring antipsychotic medication, active ongoing treatment for substance or alcohol addiction, or lack of a fixed home address upon hospital discharge.\n9. Receipt of home palliative care.\n10. Institutionalization.\n11. Classification by the attending physician as non-compliant with medical therapies, treatments, or study protocols","50 Years","90 Years",{"count":51,"type":21},92,"The purpose of this study is to evaluate the effectiveness and clinical efficiency of combining home non-invasive ventilation (NIV) with a continuous remote telemonitoring (TM) system in patients with Chronic Obstructive Pulmonary Disease (COPD) and persistent hypercapnia. In standard practice, patients with severe COPD and high carbon dioxide levels in their blood are treated with home non-invasive ventilation to support their breathing. This study compares two different care strategies over a one-year follow-up period:\n\n1. One group of patients will receive standard home non-invasive ventilation alone.\n2. Another group will receive home non-invasive ventilation combined with an automated telemonitoring system that tracks device parameters daily (such as air leaks, device usage, and breathing rates) and sends automated alerts to the healthcare team if deviations occur. The main goal of the project is to determine if adding a telemonitoring follow-up system can prevent clinical worsenings and significantly reduce the total number of days patients spend hospitalized due to severe COPD flare-ups. Additionally, the study will analyze the impact of both strategies on patients' overall health-related quality of life and the economic costs within the healthcare system.",[25,54],"Hypercapnia",[56,57,58],"Home Noninvasive Ventilation","Telemonitoring","Respiratory Insufficiency","2026-06-29",{"date":61,"type":32},"2026-07-01",{"date":63,"type":21},"2026-07",{"date":65,"type":21},"2026-12",{"name":67,"class":68},"Air Liquide Healthcare Spain","INDUSTRY",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":69},"100632806","additional-effects-of-box-breathing-technique-with-short-term-pulmonary-rehabilitation-on-dyspnea-and-functional-capacity-in-patients-with-chronic-obstructive-pulmonary-disease-100632806","NCT07518472","Additional Effects of Box Breathing Technique With Short Term Pulmonary Rehabilitation on Dyspnea and Functional Capacity in Patients With Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Age between 40-65 years\n* Both genders (male and female)\n* Grade 1-3 on mMRC scale of dyspnea\n* COPD mild stage according to global initiative for chronic obstructive lung -disease (GOLD) classification; Mild = FEV1 greater than or equal to 80% predicted\n\nExclusion Criteria:\n\n* Patients having acute exerbation of COPD\n* Patients diagnosed with acute infection (pmeumonia, T.B)\n* Any orthopedic or neuromuscular condition that hinders participation in exercise training program\n* Patients unable to follow command and instructions","40 Years","65 Years",{"count":79,"type":21},40,"INTERVENTIONAL",[82],"NA","Chronic Obstructive Pulmonary Disease is progressive and irreversible respiratory condition characterized by persistent airflow limitation leading to dyspnea and reduced functional capacity.\n\nPulmonary rehabilitation along with different technqiues of breathing exercises reduces dyspnea and enhance functional capacity by improving ventilatory efficiency, respiratory muscle control and overall exercise tolerance in patients with COPD.",[25],[86,87,88,89,90],"COPD","Short term pulmonary rehabilitation","box breathing","dyspnea","functional capacity","RECRUITING","2026-04-07",{"date":94,"type":32},"2026-04-08",{"date":96,"type":32},"2026-02-28",{"date":98,"type":21},"2026-05-15",{"name":100,"class":39},"Foundation University Islamabad",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":114,"conditions":115,"keywords":127,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":69},"100629594","expanded-studies-on-the-scapis-stockholm-reexamination-cohort-100629594","NCT07476703","Expanded Studies on the SCAPIS Stockholm Reexamination Cohort","Expanded Studies of Risk Factors for Pulmonary-, Liver-, and Cardiovascular Disease in the SCAPIS 2 Stockholm Reexamination","SCAPIS-ReEx","Inclusion Criteria: Subjects already included in the main \u002F general SCAPIS reexamination study in Stockholm.\n\nExclusion Criteria: Inability to provide consent.",true,"56 Years","74 Years",{"count":113,"type":21},1400,"The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018. The study is a collaborative effort among six university hospitals across Sweden. A follow-up study, SCAPIS 2, is conducted for half of the original participants. In Stockholm, 2,500 individuals will be re-examined at Danderyd University Hospital and Karolinska Institutet.\n\nSCAPIS 2 includes a core set of examinations involving blood sampling, questionnaires, and imaging. In addition to these, complementary local investigations are conducted to enable more detailed research questions. This protocol describes the additional studies conducted in the Stockholm cohort. All complementary assessments aim to identify risk factors for current and future lung, liver, and cardiovascular diseases.:\n\nEXTENDED SAMPLING: Saliva and Blood Samples with Blood Cell Isolation. EXTENDED QUESTIONNAIRES: Dyspnea, Sleep, Respiratory Infections, and Dental Health.\n\nEXTENDED IMAGING AND PHYSIOLOGICAL MEASUREMENTS Cardiac Ultrasound and Abdominal Aortic Measurements. Liver Elastography. Vascular Stiffness by cuff-based pulse wave analysis and Photoplethysmography (PPG). Valvular and Vascular Calcification by CT imaging.",[116,117,118,119,120,25,121,122,123,124,125,126],"Coronary Artery Disease","Arterial Stiffness, Blood Pressure","AORTIC VALVE DISEASES","Mitral Valve Stenosis and\u002For Insufficiency","Heart Failure","Steatohepatitis","Inflammation Biomarkers","Lipid Profile","Oral Microbiota","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Associated-dysfunction Steatohepatitis (MASH)",[128,129,130,86,131,132,133,134],"coronary artery disease","arterial stiffness","MASLD","inflammation","dyslipidemia","aortic aneurysm","oral microbiota","2026-03-12",{"date":137,"type":32},"2026-03-17",{"date":139,"type":32},"2024-04-08",{"date":141,"type":21},"2026-08-30",{"name":143,"class":39},"Danderyd Hospital",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":80,"phases":154,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100595993","phase-3-evaluation-of-611-in-chinese-adults-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease-100595993","NCT07039669","Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n1. Able to understand and follow the protocol requirements, and give written informed consent prior to participation voluntarily in the study.\n2. Male or female adults ages 40 to 85 years old when signing the informed consent.\n3. Current or former smokers with a smoking history of ≥10 pack-years.\n4. Documented diagnosis of COPD for at least 12 months prior to enrolment\n5. Moderate-to-severe COPD.\n6. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.\n7. Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥ 1 month prior to randomization; Double therapy (LABA + LAMA) allowed if ICS is contraindicated.\n8. Female subjects of reproductive age (and their male partners) and male subjects (and their female partners) must use highly effective contraception throughout the study period and for at least 3 months after the last dose. The subjects had no plans to pregnancy, donate sperm or donate egg during the whole study period and for at least 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Presence of a known pre-existing, clinically important lung condition other than COPD.\n2. A current diagnosis of asthma or history of asthma according to the Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.\n3. Diagnosis of α-1 anti-trypsin deficiency.\n4. Presence of an active autoimmune disease.\n5. Subjects who have any malignant tumors within 5 years prior to enrollment.\n6. Known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled.\n7. Diagnosed active parasitic infection, suspected or high risk of parasitic infection.\n8. Subjects who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n9. Known with allergic or intolerant to any biological product.\n10. Any reason which, in the opinion of investigator, would prevent the subject from participating in the study.","85 Years",{"count":153,"type":21},594,[155],"PHASE3","The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.",[25],"2025-11-17",{"date":160,"type":32},"2025-11-18",{"date":162,"type":32},"2025-07-16",{"date":164,"type":21},"2028-11",{"name":166,"class":68},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.",4,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":80,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":69},"100606624","comparative-effects-of-pilates-breathing-and-pursed-lip-breathing-on-chest-expension-and-peak-expiratory-flow-rate-in-patients-with-chronic-obstructive-lung-disease-100606624","NCT07177976","Comparative Effects of Pilates Breathing and Pursed Lip Breathing on Chest Expension and Peak Expiratory Flow Rate in Patients With Chronic Obstructive Lung Disease","Inclusion Criteria:\n\n* Age between 40-64 years\n* Both genders (male and female)\n* Grade 1-3 on mMRC scale of dyspnea\n* COPD mild stage according to global initiative for chronic obstructive lung disease (GOLD) classification; Mild = FEV1 greater than or equal to 80% predicted\n\nExclusion Criteria:\n\n* Moderate, severe and very severe stage of COPD according to GOLD classification\n* Patients having acute exerbation of COPD\n* Patients diagnosed with acute infection\n* Patients unable to follow command and instructions","64 Years",{"count":176,"type":21},46,[82],"Chronic Obstructive Pulmonary Disease is a particular type of irreversible disease that may damage or obstruct airways and make it difficult to breath. This respiratiry condition may lead to shallow breathing.\n\nBreathing exercisers help to manage hyperventilation often seen in COPD patients. To handle respiratory complications patients are advised to practice breathing techniques along with pharmacological management",[25],[181,182,89],"Chest expansion","peak expiratory flow rate","2025-10-02",{"date":185,"type":32},"2025-10-07",{"date":187,"type":32},"2025-09-15",{"date":189,"type":21},"2026-02-01",{"name":100,"class":39}]